A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Sagimet Biosciences Inc.
SGMT
$226M
Mkt Cap
$7.07
+0.86%
Sagimet Biosciences Inc. (SGMT) has a 5-year average return on invested capital (ROIC) of -30.6%. This is below average and may indicate limited pricing power.
Sagimet Biosciences Inc. (SGMT) has a market capitalization of $219M. It is classified as a small-cap stock.
Sagimet Biosciences Inc. (SGMT) does not currently pay a regular dividend.
Sagimet Biosciences Inc. (SGMT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Sagimet Biosciences Inc. (SGMT) generated $-24 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Sagimet Biosciences Inc. (SGMT) has a debt-to-equity ratio of 0.06. This indicates a conservatively financed balance sheet.
Sagimet Biosciences Inc. (SGMT) reported earnings per share (EPS) of $-2.66 in its most recent fiscal year.
We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). Denifanstat has been studied in over 740 people to date in our clinical trials, including our Phase 2 FASCINATE-1 and Phase 2b FASCINATE-2 clinical trials. In January 2024, we announced positive topline results from the Phase 2b FASCINATE-2 clinical trial evaluating denifanstat in 168 biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52.
| Segment | 2023 | % of Total |
|---|---|---|
Operating segment | $2M | 100% |
| Metric | TTM | FY2023 |
|---|---|---|
| Revenue | 0 | - |
| Net Income | -58M | -28M |
| EPS | $-1.78 | $-2.66 |
| Free Cash Flow | 0 | -24M |
| ROIC | -1983.3% | -30.6% |
| Gross Margin | - | - |
| Debt/Equity | 0.00 | 0.06 |
| Dividends/Share | $0.00 | - |
| Operating Income | -64M | -31M |
| Operating Margin | 0.0% | - |
| ROE | -48.4% | -30.6% |
| Shares Outstanding | 31M | 32M |
| Metric | ||
|---|---|---|
| Income Statement | ||
| Revenue | N/A | 0 |
| Gross Margin | N/A | N/A |
| R&D | 20M | 20M |
| SG&A | 13M | 13M |
| EBIT | -31M | -64M |
| Op. Margin | N/A | 0.0% |
| Net Income | -28M | -58M |
| Net Margin | N/A | 0.0% |
| Non-Recurring | 0 | 0 |
| Returns on Capital | ||
| ROIC | -30.6% | N/M |
| ROE | -30.6% | -48.4% |
| ROA | -43.0% | -44.9% |
| Cash Flow | ||
| Op. Cash Flow | -24M | -45M |
| Free Cash Flow | -24M | 0 |
| Owner Earnings | -29M | -50M |
| CapEx | 0 | 0 |
| Maint. CapEx | 0 | 0 |
| Growth CapEx | N/A | 0 |
| D&A | 0 | 0 |
| CapEx/OCF | N/A | 0.0% |
| Capital Allocation | ||
| Dividends Paid | 0 | 0 |
| Dividend Yield | N/A | N/A |
| Share Buybacks | 0 | 0 |
| Buyback Yield | N/A | 0.0% |
| Stock-Based Comp | 5.0M | 5.0M |
| Debt Repayment | 0 | 0 |
| Balance Sheet | ||
| Net Debt | N/A | -117M |
| Cash & Equiv. | 75M | 117M |
| Long-Term Debt | N/A | N/A |
| Debt/Equity | 0.06 | 0.00 |
| Interest Coverage | N/A | N/A |
| Equity | 91M | 119M |
| Total Assets | 97M | 128M |
| Total Liabilities | 5.7M | 4.8M |
| Intangibles | N/A | N/A |
| Retained Earnings | -250M | -337M |
| Working Capital | 91M | 110M |
| Current Assets | 97M | 119M |
| Current Liabilities | 5.7M | 9.1M |
| Per Share Data | ||
| EPS | -2.66 | -1.78 |
| Owner EPS | -0.90 | -1.61 |
| Book Value | 2.85 | 3.85 |
| Cash Flow/Share | -0.74 | -1.86 |
| Dividends/Share | N/A | 0.00 |
| Shares Out. | 31.9M | 31.0M |
| Valuation | ||
| P/E Ratio | N/A | -4.0 |
| P/FCF | N/A | N/A |
| EV/EBIT | N/A | N/A |
| Price/Book | 0.7 | 1.8 |
| Price/Sales | N/A | N/A |
| FCF Yield | -38.5% | N/A |
| Market Cap | 62M | 219M |
| Avg. Price | 8.75 | 7.07 |
| Year-End Price | 5.89 | 7.07 |
Sagimet Biosciences Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Sagimet Biosciences Inc. (SGMT) has a return on equity (ROE) of -30.6%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 1 years of financial data for Sagimet Biosciences Inc. (SGMT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Sagimet Biosciences Inc. (SGMT) has a book value per share of $2.85, based on its most recent annual SEC filing.